The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| DYN | +18.51% | -7.01% | -1.44% | -39% |
| S&P | +16.53% | +80.89% | +12.59% | +103% |
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.
This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach.
The company is attracting much investor attention this week because of what happened in the lab.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$521.00K | 48.9% |
| Market Cap | $3.16B | 32.0% |
| Market Cap / Employee | $12.27M | -2.3% |
| Employees | 258 | 35.1% |
| Net Income | -$111,955.00K | -25.0% |
| EBITDA | -$115,608.00K | -20.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $893.37M | 105.2% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $164.20M | 758.0% |
| Short Term Debt | $5.00M | 3.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -47.52% | 26.6% |
| Return On Invested Capital | -74.26% | 11.4% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$112,316.00K | -31.5% |
| Operating Free Cash Flow | -$111,832.00K | -32.6% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.70 | 1.62 | 2.53 | 4.03 | 18.68% |
| Price to Tangible Book Value | 1.70 | 1.62 | 2.53 | 4.03 | 18.68% |
| Enterprise Value to EBITDA | -14.71 | -4.30 | -4.60 | -9.71 | -68.10% |
| Return on Equity | -64.0% | -61.3% | -60.7% | -55.7% | -36.72% |
| Total Debt | $23.33M | $121.08M | $120.47M | $169.20M | 605.35% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
